| | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = $38,679,725 ) (Continued on the next page) |
| | 2021 | 2021 | R01AI109842 | NFAT, bZIP proteins, and transcriptional programs in lymphocytes | 000 | 33 | NIH | 2/12/2021 | 603880287 | $842,353 |
| | 2021 | 2021 | U01CA224766 | Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers | 000 | 4 | NIH | 4/19/2021 | 603880287 | $136,148 |
| | 2021 | 2021 | R01CA247500 | Exploring the potential of TET inhibition in cancer immunotherapy | 000 | 2 | NIH | 6/30/2021 | 603880287 | $502,630 |
| | 2021 | 2021 | U19AI142742 | Functional and dysfunctional human CD4 T cell and B cell responses to bacteria and viruses | 000 | 2 | NIH | 11/18/2020 | 603880287 | $1,263,917 |
| | 2021 | 2021 | U19AI142742 | Functional and dysfunctional human CD4 T cell and B cell responses to bacteria and viruses | 001 | 3 | NIH | 3/15/2021 | 603880287 | $2,658,245 |
| | 2021 | 2021 | U19AI142742 | Functional and dysfunctional human CD4 T cell and B cell responses to bacteria and viruses | 002 | 3 | NIH | 3/17/2021 | 603880287 | $5,161,678 |
| | 2021 | 2021 | R01AI137230 | Host nutrients permit immune evasion of NKT cell anti-bacterial responses | 000 | 4 | NIH | 12/7/2020 | 603880287 | $615,389 |
| | 2021 | 2021 | F32AI147531 | Rabies virus glycoprotein structure determination and receptor binding interactions | 000 | 3 | NIH | 6/16/2021 | 603880287 | $5,714 |
| | 2021 | 2021 | R01AI139749 | CD4 T cell control of cytomegalovirus | 000 | 3 | NIH | 1/15/2021 | 603880287 | $615,063 |
| | 2021 | 2021 | R01CA256133 | Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy | 000 | 1 | NIH | 7/8/2021 | 603880287 | $783,417 |
| | 2021 | 2021 | U24CA248138 | THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE | 000 | 1 | NIH | 5/5/2021 | 603880287 | $839,852 |
| | 2021 | 2021 | U19AI135731 | LJI Epitope Validation Center: Characterization of epitope-specific T cells responding to food, fungal and inner city allergens | 000 | 4 | NIH | 12/23/2020 | 603880287 | $1,079,306 |
| | 2021 | 2021 | R01AR072640 | TWEAK and Skin Inflammation | 000 | 4 | NIH | 4/30/2021 | 603880287 | $384,120 |
| | 2021 | 2021 | R01AI134971 | Integrated Functional Histopathology of the Diabetic Human Pancreas | 000 | 4 | NIH | 11/20/2020 | 603880287 | $699,000 |
| | 2021 | 2021 | U01AI141995 | Identifying mechanisms and correlates of long-lasting vaccine-induced immunity to whooping cough | 000 | 3 | NIH | 11/18/2020 | 603880287 | $823,202 |
| | 2021 | 2021 | R01CA233862 | A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy | 002 | 3 | NIH | 3/26/2021 | 603880287 | $0 |
| | 2021 | 2021 | R01CA233862 | A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy | 001 | 3 | NIH | 2/2/2021 | 603880287 | $26,153 |
| | 2021 | 2021 | R01CA233862 | A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy | 000 | 3 | NIH | 11/30/2020 | 603880287 | $496,910 |
| | 2021 | 2021 | K99CA248835 | Tumor suppressive functions of TET proteins in B cell malignancies: role of G-quadruplex structures | 000 | 2 | NIH | 2/2/2021 | 603880287 | $144,720 |
| | 2021 | 2021 | R01AI092453 | Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes | 000 | 10 | NIH | 11/17/2020 | 603880287 | $450,000 |
| | 2021 | 2021 | U19AI142790 | Consortium for Immunotherapeutics against Emerging Viral Threats | 001 | 3 | NIH | 5/6/2021 | 603880287 | $7,065,330 |
| | 2021 | 2021 | R21AI153867 | Crosstalk between FceRI and MAVS signaling pathways in mast cells | 000 | 2 | NIH | 4/6/2021 | 603880287 | $228,750 |
| | 2021 | 2021 | R01AI128589 | Epigenetic control of Foxp3 expression in induced T regulatory cells | 000 | 5 | NIH | 5/25/2021 | 603880287 | $450,000 |
| | 2021 | 2021 | U19AI118626 | Human immune signatures of Dengue virus and Mycobacterium Tuberculosis exposure in infection, disease and vaccination | 000 | 7 | NIH | 6/3/2021 | 603880287 | $2,721,262 |
| | 2021 | 2021 | U19AI118626 | Human immune signatures of Dengue virus and Mycobacterium Tuberculosis exposure in infection, disease and vaccination | 001 | 7 | NIH | 6/9/2021 | 603880287 | $292,800 |
| | 2021 | 2021 | R01AI135193 | CD4 T cell, germinal center, and antibody response defects in recurrent tonsillitis | 000 | 4 | NIH | 5/25/2021 | 603880287 | $450,000 |
| | 2021 | 2021 | F31DK124078 | The Role of Intestinal Epithelial Cells in the Generation of Protective CD4 Cytotoxic T Lymphocytes | 000 | 2 | NIH | 2/4/2021 | 603880287 | $40,450 |
| | 2021 | 2021 | U01AI150753 | Developing computational models to predict the immune response to B. pertussis booster vaccination | 000 | 2 | NIH | 3/12/2021 | 603880287 | $1,350,044 |
| | 2021 | 2021 | R01AI163188 | Development of a Replicon RNA-based Vaccine against Dengue and Zika | 000 | 1 | NIH | 5/27/2021 | 603880287 | $712,699 |
| | 2021 | 2021 | R01AI121426 | Epigenome-wide association study of childhood asthma | 000 | 5 | NIH | 12/1/2020 | 603880287 | $784,641 |
| | 2021 | 2021 | P01HL136275 | Immune Cell Interactions in Atherosclerosis | 000 | 5 | NIH | 6/18/2021 | 603880287 | $2,577,670 |
| | 2021 | 2021 | R35HL145241 | Vascular macrophages and T cells in atherosclerosis | 000 | 3 | NIH | 3/10/2021 | 603880287 | $907,152 |
| | 2021 | 2021 | R01AI143934 | The Role of Cytoplasmic and Nuclear THEMIS in Immature and Mature T cells | 000 | 2 | NIH | 1/22/2021 | 603880287 | $688,446 |
| | 2021 | 2021 | R01AI153500 | Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis | 000 | 1 | NIH | 3/5/2021 | 603880287 | $725,399 |
| | 2021 | 2021 | R37AI125068 | Maximizing germinal centers and somatic hypermutation to HIV Env immunogens | 000 | 6 | NIH | 2/11/2021 | 603880287 | $922,142 |
| | 2021 | 2021 | R01DK114457 | LIGHT/TNFSF14 in allergic esophagitis remodeling | 000 | 4 | NIH | 2/25/2021 | 603880287 | $568,901 |
| | 2021 | 2021 | R01AI101423 | The role of TRAIL in immune control of cytomegalovirus | 000 | 8 | NIH | 5/25/2021 | 603880287 | $549,000 |
| | 2021 | 2020 | R01CA202987 | Functions of Nonclassical Monocytes in the Vasculature | 000 | 5 | NIH | 6/22/2021 | 603880287 | $0 |
| | 2021 | 2020 | F30AI136410 | Targeted therapeutics against filoviral hemorrhagic fever | 000 | 4 | NIH | 6/16/2021 | 603880287 | -$50,520 |
| | 2021 | 2020 | U01CA260588 | SARS-CoV-2-reactive tissue-resident memory T cells in healthy and cancer subjects | 000 | 1 | NIH | 12/30/2020 | 603880287 | $0 |
| | 2021 | 2020 | U19AI142790 | Consortium for Immunotherapeutics against Emerging Viral Threats | 002 | 2 | NIH | 5/12/2021 | 603880287 | $0 |
| | 2021 | 2020 | U19AI142790 | Consortium for Immunotherapeutics against Emerging Viral Threats | 000 | 2 | NIH | 4/6/2021 | 603880287 | $0 |
| | 2021 | 2020 | R56AI148635 | Development of a Replicon RNA-based Universal Vaccine against Dengue and Zika | 000 | 1 | NIH | 5/19/2021 | 603880287 | $0 |
| | 2021 | 2020 | U19AI118626 | Human immune signatures of Dengue virus and Mycobacterium Tuberculosis exposure in infection, disease and vaccination | 003 | 6 | NIH | 6/24/2021 | 603880287 | $94,184 |
| | 2021 | 2020 | R21AI145374 | Genetic contributions to T cell mediated immunopathology after viral infection | 001 | 3 | NIH | 2/10/2021 | 603880287 | $189,387 |
| | 2021 | 2020 | R01AI109842 | NFAT, bZIP proteins, and transcriptional programs in lymphocytes | 001 | 32 | NIH | 6/3/2021 | 603880287 | $226,212 |
| | 2021 | 2019 | R21AI140063 | Vaginal Adaptive Immunity Against Zika Virus | 000 | 2 | NIH | 11/20/2020 | 603880287 | $0 |
| | 2021 | 2019 | R01CA199376 | Targeting tumor endothelium for cancer surveillance and immunotherapy | 000 | 5 | NIH | 3/10/2021 | 603880287 | $0 |
| | 2021 | 2019 | R56AI109842 | NFAT, bZIP proteins, and transcriptional programs in lymphocytes | 000 | 32 | NIH | 6/3/2021 | 603880287 | -$226,212 |
|
